Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium infantis EVC001 + lacto-N-tetraose
- Development stage
- Unknown
- Lead developer
- Evolve BioSystems
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis EVC001 + lacto-N-tetraose is a synbiotic combination developed by Evolve BioSystems, Inc. It consists of a specific probiotic bacterial strain, *Bifidobacterium longum* subspecies *infantis* EVC001, and a prebiotic human milk oligosaccharide (HMO), lacto-N-tetraose (LNT). This combination is designed to establish a healthy gut microbiome in infants, particularly those who are breastfed or preterm. *B. infantis* EVC001 is uniquely equipped with the genetic machinery to fully metabolize HMOs like LNT, allowing it to outcompete potentially pathogenic bacteria, lower intestinal pH, and support immune development. The product is being investigated for the prevention of necrotizing enterocolitis (NEC) in preterm infants, the treatment of severe acute malnutrition, and the management of infant colic.
- Brand names
- Evivo
- Other names
- Bifidobacterium longum subsp. infantis EVC001 + lacto-N-tetraoseB. infantis EVC001 + LNTBifidobacterium longum subspecies infantis strain EVC001 + lacto-N-tetraose
Beyond the preview
Go deeper on Bifidobacterium infantis EVC001 + lacto-N-tetraose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium infantis EVC001 + lacto-N-tetraose.